|
|
Profile
|
Delegates :
Tadashi Matsuda |
|
Incorporated :
February 1 , 2018 |
Paid in Capital :
9 Million yen |
Employees :
7 人 |
Address :
Sunterras Mikawaanjou, Mikawaanjou Minamimachi 1-15-8, Anjou-si AICHI
〒446-0058
|
TEL/FAX :
+81-566-71-5901 / |
URL：
https://www.sapalaorganics.com/#/SapalaOrganic |
Attachment :
|
Mission/Background :
|
|
Technology & Business
|
Sapara supports new drug discovery research and development by providing research, synthesis, manufacturing, process development, and analysis of new modalities (e.g., modified nucleic acids) and new small molecule drug discovery. We have a research building of over 6,000 m2 with state-of-the-art facilities and equipment, and our team of over 250 researchers, most of whom are Ph.D.-degreed, provide support from lead generation to industrial production. We are particularly confident in our synthesis technologies for modified nucleic acids and nucleic acid oligomers, and in the synthesis of payloads and linkers for antibody-drug conjugates (ADCs).
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
Synthesis artificial nucleic acids, nucleic acid oligomers and antisense nucleic acids
|
Service/Marketing
|
Out-licensing product/technology, Selling/suggesting product/service
|
|
Payload synthesis of antibody-drug conjugates
|
Service/Marketing
|
Out-licensing product/technology, Selling/suggesting product/service
|
|
API production of low-molecular-weight drugs
|
Service/Marketing
|
Out-licensing product/technology, Selling/suggesting product/service
|
|
Modified Nucleic Acid Monomers, CRO, CDMO
|
Service/Marketing
|
Out-licensing product/technology, Selling/suggesting product/service
|
|
|
|
|
|
|
|